HIV research findings made possible by a test developed at CU School of Pharmacy

July 28, 2014

An influential new test, discovered and developed in the Colorado Antiviral Pharmacology Laboratory at the CU School of Pharmacy, helps monitor the effectiveness of the HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), which is taken once daily to prevent HIV infection.

A study presented during the AIDS 2014 Conference and published in Lancet Infectious Diseases on the efficacy and safety of prophylactic use of Truvada to protect against HIV infection relied on a test developed at the school. The test measures the amount of tenofovir-diphosphate (a metabolite of tenofovir) in , using a dried blood spot. Because of a long half-life, high amounts of the metabolite in the dried blood spot correspond with consistent dosing of Truvada and low amounts correspond with inconsistent dosing. The new test was used in the iPrEx open label extension study (iPrEx OLE) to estimate patterns of tablet use during the study. The new test showed a continuous gradient of increasing efficacy (fewer HIV infections) with increasing drug concentrations. Dr. Peter Anderson, whose laboratory developed the test, said, "Participants in the study who had tablet use consistent with 4 or more tablets per week, as determined by the new test, had no HIV infections (estimated 100% efficacy)."

The US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recently issued guidelines recommending the use of antiretroviral medicines as an additional method of preventing HIV infection. "Findings from iPrEX OLE are particularly important in relation to emerging guidelines recommending widespread use of PrEP," said Protocol Chair Robert Grant, MD, PGH of the Gladstone Institutes, the University of California at San Francisco and the San Francisco AIDS Foundation.

Explore further: UNAIDS welcomes US approval of drug to stop HIV

Related Stories

NIH-funded analysis estimates effective PrEP dosing

September 13, 2012

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP. The level ...

HIV pills show more promise to prevent infection

July 22, 2014

There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage ...

Recommended for you

Videos reveal how HIV spreads in real time

October 2, 2015

How retroviruses like HIV spread in their hosts had been unknown—until a Yale team devised a way to watch it actually happen in a living organism. The elaborate and sometimes surprising steps the virus takes to reach and ...

Researchers find proteins that shut down HIV-1

September 30, 2015

A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University of Geneva in Switzerland, point to a promising new anti-retroviral strategy for combating ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.